Irritable Bowel Syndrome
Conditions
Keywords
IBS, dietary treatment, digital
Brief summary
Two carbohydrate reduced diets, the low FODMAP diet (LFD) and low-carbohydrate diet (LCD), have in randomized controlled studies shown efficacy in relieving symptoms in patients with Irritable Bowel Syndrome (IBS), but access to trained dieticians is limited. Digital delivery may offer a convenient, cost-effective and scalable solution. This pilot study aims to evaluate the effectiveness and feasibility of digitally delivered evidence-based dietary treatments in relieving gastrointestinal, psychological and somatic symptoms and improving quality of life in patients with IBS. Adults with IBS will be recruited via social media and clinical referrals and will receive their choice of the two dietary treatments: LFD with traditional IBS dietary advice or LCD. Participants will get access to the digital platform which contains information about the study, IBS pathophysiology, the treatment diet along with recipes and a mobile application for food scanning. Participants will complete digital questionnaires at baseline and week four to evaluate changes in gastrointestinal symptoms (IBS-SSS), somatic and psychological symptoms (PHQ-15, HADS, VSI) and quality of life (IBS-QoL). Feasibility and adherence is assessed with an evaluation questionnaire.
Interventions
OTHERDigital dietary platform
a digital platform with information about the study, IBS, the treatment diet along with recipes and a mobile application for food scanning.
Sponsors
Sahlgrenska University Hospital
Funding: Kostfonden
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Effect of digital dietary treatment with either of the two treatments diets. Participants choose from the two diets.
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with IBS (Rome IV) by physician * Age 18-64 * Ability to read and understand Swedish * Signed informed consent
Exclusion criteria
* Received dietary treatmen for IBS previously * Manifestations of other conditions that may explain gastrointestinal symptoms * Manifestation of other serious medical conditions * Patients with ongoing eating disorders * Pregnant/lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with significant gastrointestinal symtom reduction | From baseline vs 4 weeks after starting digital dietary treatment. | A responder to treatment is defined as having a symptom reduction \> 50 measured by IBS-SSS |
Countries
Sweden
Outcome results
None listed